Skip to main content
NVDA+0.57%AAPL+0.41%GOOGL+0.93%MSFT+0.39%AMZN+0.36%TSM-0.16%SPCX+1.09%META+0.17%AVGO-1.10%TSLA+0.05%SKHY-1.36%MU+0.23%LLY-2.33%BRK-B-0.88%AMD+0.69%JPM-1.24%WMT-2.70%ASMLa-0.27%XOM+0.87%V-1.79%JNJ-1.06%INTC+3.71%0700.HK-0.23%MA-2.15%1398.HK+0.78%ABBV-0.65%CSCO+0.65%LRCX+1.44%CVX-0.08%AMAT-0.12%COST-1.54%AP2d+1.46%ORCL-0.35%BAC-0.96%CAT-1.92%KO-0.88%DELL-0.30%0005.HK-0.63%PG-2.05%HSBA.L-0.64%UNH-2.10%3988.HK+1.16%GE-1.76%1816.HK+0.48%ARM-1.37%0857.HK-0.51%0939.HK+1.34%1288.HK+0.61%PM-1.59%MS-2.43%GBPAUD+1.23%AUDUSD-1.17%GBPCHF+1.02%USDCHF+0.94%GBPNZD+0.79%GBPCAD+0.79%NZDUSD-0.75%USDCAD+0.73%AUDJPY-0.69%EURGBP-0.65%USDTHB+0.64%EURAUD+0.60%EURUSD-0.60%GBPJPY+0.57%USDJPY+0.51%AUDCAD-0.47%AUDNZD-0.43%GBPTRY+0.41%CHFJPY-0.40%PLNJPY+0.39%EURCHF+0.34%GBPHKD+0.32%SGDJPY+0.32%USDTRY+0.29%NOKJPY+0.29%GBPMXN-0.28%AUDCHF-0.26%NZDJPY-0.22%CADCHF+0.22%CADJPY-0.21%NZDCHF+0.20%USDZAR+0.20%USDSEK+0.17%EURNZD+0.16%USDILS+0.16%USDMXN+0.14%USDCNH-0.14%USDNOK+0.13%EURCAD+0.13%EURZAR+0.13%GBPZAR+0.11%NZDSGD-0.11%EURSEK+0.11%CHFSEK+0.10%USDSGD+0.10%AUDNOK+0.10%EURJPY-0.09%NZDMXN-0.09%EURNOK+0.09%CHFNOK+0.08%EURHKD-0.07%GBPUSD+0.06%AUDSGD+0.06%USDDKK+0.05%EURSGD+0.04%USDCOP-0.04%USDPLN+0.04%CHFSGD+0.04%USDHKD+0.03%GBPSGD+0.02%EURPLN-0.02%NZDCAD-0.01%AUDDKK+0.01%EURCNH0.00%EURDKK0.00%EURCZK0.00%XAGUSD+0.70%GAGUSD+0.70%HG1-0.64%USOIL-0.49%UKOIL-0.33%S1-0.27%XPTUSD-0.25%COTTON-0.21%XNGUSD-0.08%GAUUSD-0.06%XAUUSD-0.06%C1+0.03%BTCUSD-0.19%ETHUSD+7.44%USDTUSD-0.03%XRPUSD+0.63%SOLUSD-0.64%TRXUSDT+1.07%ZECUSDT-0.02%DOGEUSD-0.17%LINKUSD-2.08%XMRUSDT+0.57%XLMUSD+2.18%BCHUSDT-0.61%UNIUSD-0.74%LTCUSD+0.07%SUIUSD+1.70%HBARUSDT+1.75%TONUSD+15.77%TAOUSDT+0.27%AAVEUSD-2.45%DOTUSDT+2.87%ICPUSDT-1.58%ONDOUSDT+0.21%WLDUSDT+10.30%ARBUSDT-0.33%JUPUSDT-1.11%ATOMUSDT+1.34%INJUSDT-3.04%STXUSDT+18.01%FETUSDT+3.26%SEIUSDT+0.33%PYTHUSDT-3.04%TIAUSDT-0.07%IMXUSDT+0.97%GRTUSDT-0.44%OPUSDT-0.24%WIFUSDT+3.87%IOTAUSDT+4.03%POLUSDT-4.75%AXSUSDT+0.76%FARTCOINUSDT-0.30%EOSUSDT+4.07%DYDXUSDT+3.32%GALAUSDT+3.85%ORDIUSDT+1.22%NOTUSDT+1.55%RONINUSDT+0.06%NVDA+0.57%AAPL+0.41%GOOGL+0.93%MSFT+0.39%AMZN+0.36%TSM-0.16%SPCX+1.09%META+0.17%AVGO-1.10%TSLA+0.05%SKHY-1.36%MU+0.23%LLY-2.33%BRK-B-0.88%AMD+0.69%JPM-1.24%WMT-2.70%ASMLa-0.27%XOM+0.87%V-1.79%JNJ-1.06%INTC+3.71%0700.HK-0.23%MA-2.15%1398.HK+0.78%ABBV-0.65%CSCO+0.65%LRCX+1.44%CVX-0.08%AMAT-0.12%COST-1.54%AP2d+1.46%ORCL-0.35%BAC-0.96%CAT-1.92%KO-0.88%DELL-0.30%0005.HK-0.63%PG-2.05%HSBA.L-0.64%UNH-2.10%3988.HK+1.16%GE-1.76%1816.HK+0.48%ARM-1.37%0857.HK-0.51%0939.HK+1.34%1288.HK+0.61%PM-1.59%MS-2.43%GBPAUD+1.23%AUDUSD-1.17%GBPCHF+1.02%USDCHF+0.94%GBPNZD+0.79%GBPCAD+0.79%NZDUSD-0.75%USDCAD+0.73%AUDJPY-0.69%EURGBP-0.65%USDTHB+0.64%EURAUD+0.60%EURUSD-0.60%GBPJPY+0.57%USDJPY+0.51%AUDCAD-0.47%AUDNZD-0.43%GBPTRY+0.41%CHFJPY-0.40%PLNJPY+0.39%EURCHF+0.34%GBPHKD+0.32%SGDJPY+0.32%USDTRY+0.29%NOKJPY+0.29%GBPMXN-0.28%AUDCHF-0.26%NZDJPY-0.22%CADCHF+0.22%CADJPY-0.21%NZDCHF+0.20%USDZAR+0.20%USDSEK+0.17%EURNZD+0.16%USDILS+0.16%USDMXN+0.14%USDCNH-0.14%USDNOK+0.13%EURCAD+0.13%EURZAR+0.13%GBPZAR+0.11%NZDSGD-0.11%EURSEK+0.11%CHFSEK+0.10%USDSGD+0.10%AUDNOK+0.10%EURJPY-0.09%NZDMXN-0.09%EURNOK+0.09%CHFNOK+0.08%EURHKD-0.07%GBPUSD+0.06%AUDSGD+0.06%USDDKK+0.05%EURSGD+0.04%USDCOP-0.04%USDPLN+0.04%CHFSGD+0.04%USDHKD+0.03%GBPSGD+0.02%EURPLN-0.02%NZDCAD-0.01%AUDDKK+0.01%EURCNH0.00%EURDKK0.00%EURCZK0.00%XAGUSD+0.70%GAGUSD+0.70%HG1-0.64%USOIL-0.49%UKOIL-0.33%S1-0.27%XPTUSD-0.25%COTTON-0.21%XNGUSD-0.08%GAUUSD-0.06%XAUUSD-0.06%C1+0.03%BTCUSD-0.19%ETHUSD+7.44%USDTUSD-0.03%XRPUSD+0.63%SOLUSD-0.64%TRXUSDT+1.07%ZECUSDT-0.02%DOGEUSD-0.17%LINKUSD-2.08%XMRUSDT+0.57%XLMUSD+2.18%BCHUSDT-0.61%UNIUSD-0.74%LTCUSD+0.07%SUIUSD+1.70%HBARUSDT+1.75%TONUSD+15.77%TAOUSDT+0.27%AAVEUSD-2.45%DOTUSDT+2.87%ICPUSDT-1.58%ONDOUSDT+0.21%WLDUSDT+10.30%ARBUSDT-0.33%JUPUSDT-1.11%ATOMUSDT+1.34%INJUSDT-3.04%STXUSDT+18.01%FETUSDT+3.26%SEIUSDT+0.33%PYTHUSDT-3.04%TIAUSDT-0.07%IMXUSDT+0.97%GRTUSDT-0.44%OPUSDT-0.24%WIFUSDT+3.87%IOTAUSDT+4.03%POLUSDT-4.75%AXSUSDT+0.76%FARTCOINUSDT-0.30%EOSUSDT+4.07%DYDXUSDT+3.32%GALAUSDT+3.85%ORDIUSDT+1.22%NOTUSDT+1.55%RONINUSDT+0.06%
AL

Alkermes plc (ALKS)

NASDAQ • Healthcare

$40.52
-$0.27 (-0.7%)
Market closed

Last close at September 30, 2026 at 20:00 UTC

Open$40.94
Day Range$39.92 - $40.94
Avg. Volume (3M)2.2M
Market Cap$6.7B
P/E Ratio101.3
52 Week Range
$27$55.67
Next EarningsIn 27 daysOct 28, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$496M100%
Gross Profitminus cost of goods$397.8M80%
Operating Incomeminus R&D and overhead$18.3M4%
Net Incomeminus taxes and the rest$501K0%

Fundamentals & Financials

Revenue (TTM)
$1.6B
Net Income (TTM)
$66.1M
EPS (TTM)
$0.4
ROA (TTM)
1.51%
Current Ratio
2.3
Dividend Yield
0%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-20.9%Q1 2026$0.34
+29.8%Q2 2026-$0.4
+2650.1%Q3 2026$0.7
Next

Oct 28

in 27 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +2650.1%

Alkermes topped consensus revenue expectations in the second fiscal quarter of 2026, with results reported July 28, 2026, as revenue rose 27% to about $496.0 million (up from roughly $390.7 million a year ago) and came in at $496.0 million versus a $457.4 million estimate, +8.4% (topped). Adjusted EPS was $0.70, while profitability included gross profit of about $397.9 million with gross margin near 80% and operating income of roughly $18.4 million, translating to an operating margin of around 4%. The company generated operating cash flow of about $145.2 million during the quarter. For the next period, consensus calls for EPS of $-0.08 on revenue of $463.9 million.

Next report — what to expect

Alkermes plc (ALKS) reports next on October 28, 2026. Wall Street expects EPS of -$0.08 on revenue of $463.5 million. For trailing context, revenue grew +27.0% year over year last quarter. Alkermes has beaten EPS in 5 of 8 most recent quarters, making profit delivery a key watch item.

View full earnings history

About Alkermes plc

Alkermes plc is a biotechnology company listed on NASDAQ as ALKS that develops and commercializes central nervous system medicines and related drug-delivery capabilities. Its portfolio spans schizophrenia, addiction, bipolar disorder, and sleep disorders, and it generated $1.5 billion of revenue in FY2025.

Name
Alkermes plc
CEO
Blair Jackson
Website
www.alkermes.com
Industry
Healthcare
Year Founded
1987
Employees
2,050

Today's Snapshot

AI-generated

ALKS closed 0.7% below yesterday's close, in line with a weaker sector.

Trading Volume

Below 10d avg (2.9M)

2M

vs S&P 500 Today

Underperforming Market

-0.88%

Updated: September 30, 2026 at 20:20 UTC

Technical Indicators

3 Buy0 Neutral5 Sell
ALKS reflects a sell bias driven by a strong ADX indicating a pronounced downtrend along with negative momentum and a notably bearish MACD. Short- and medium-term moving averages sit above the current price even though the 200-day average is lower, suggesting recent strength remains in a longer-term context yet is overwhelmed by near-term selling. OBV is negative, confirming distribution, and ATR points to moderate volatility. The pivot is essentially at the market price and offers no countervailing signal. Technical takeaway: Sell.
All signals
  • EMA (5 indicators)$39.66 - $45.81
    Sell
  • RSI (14)27.98
    Buy
  • Stochastic %K (14, 3, 3)7.73
    Buy
  • MACD Level (12, 26)-2.02
    Sell

Peers & Related Assets

ARWRArrowhead Pharmaceuticals, Inc.
$65.45-1.2%
KYMRKymera Therapeutics, Inc.
$111.79+1.2%
PTGXProtagonist Therapeutics, Inc.
$140.89-0.1%
TGTXTG Therapeutics, Inc.
$55.78-0.7%
PCVXVaxcyte, Inc.
$56.9+0.4%
PTCTPTC Therapeutics, Inc.
$64.78-0.3%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.